The Visica 2 Treatment System is an effective alternative to surgery for benign breast tumors


Until a year ago, I was treating biopsy-proven fibroadenomas by either observation or surgical excision. While I find surgical excision effective, the drawbacks include the need for general anesthesia, increased patient stress, recovery time, and based on fibroadenoma size — scarring and potential disfigurement. Observation can also be stressful on patients, especially when their fibroademomas are larger than 1 centimeter. Wanting a minimally invasive alternative for my patients with symptomatic fibroadenomas, I identified the Sanarus Visica 2 System that utilizes cryoablation to destroy fibroadenomas. After 12 months of use in my practice, I have found this therapy to be ideal in treating these symptomatic fibroadenomas from both the physician and the patient perspective.
The first advantage of cryoablation over surgery that I noted is that I can treat fibroadenomas quickly and easily in my office. This makes scheduling easier and has helped facilitate more treatments while reducing overall costs to my patients as co-pays are less. When performing Visica treatments, I use ultrasound to guide the cryoprobe into position in the lesion and to monitor a growing ice ball that engulfs the fibroadenoma as it moves through freeze/thaw cycles which destroy the targeted tissue. The Visica 2 treatment also affords me the opportunity to control the iceball size relative to the size of the lesion, giving me the ability to tailor my treatments to specific lesion sizes. The speed of the treatment was surprising. I’ve found treatment times for lesions 2 centimeters to be around 12 minutes. That combined with the use of local anesthesia makes the treatment stress-free on my patients.
Long-term results have also been impressive. Clinical studies have shown no regrowth in over 1,500 cases, which has also been demonstrated in my practice. Resolution has been rapid, especially with tumors under 2 centimeters in size that resolve in less than six months. Additionally, published clinical data demonstrates that cryotherapy does not produce artifacts in follow-up mammograms that would adversely affect interpretation. I have found follow-up mammography to be essentially normal in my patients.
Overall, I would describe the key difference between treating with cryotherapy versus surgical and percutaneous excision as the ability to perform a minimally invasive treatment that destroys the entire fibroadenoma with little or no risk. The ablated tissue essentially “melts away” over time, permanently ridding my patients of the fibroadenoma. They are left with virtually no scarring and no deformity as I’m not removing any tissue from the breast. In fact, the incision needed to accommodate the probe is always around 3 mm whether I treat a 1- or a 4-cm fibroadenoma. The patients have reduced stress because they can have the treatment in my office, and there’s no recovery time so they are immediately back to normal activities.

For more information: www.sanarus.com


Related Content

News | Breast Biopsy Systems

July 7, 2021 — GE Healthcare announced the installation of Serena Bright in five hospitals and radiology centers around ...

Time July 07, 2021
arrow
News | Breast Imaging

January 4, 2021 — Hologic, Inc. announced it has completed the acquisition of SOMATEX Medical Technologies GmbH, a ...

Time January 04, 2021
arrow
News | Prostate Cancer

According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer in their lifetime. It’s both the second most common cancer and second most common cause of cancer death in American men. Early detection is critical and can increase a man’s chances of survival.

Time August 20, 2019
arrow
News | Biopsy Systems

Dune Medical Devices has just completed the first in-man cases for Smart Biopsy, its percutaneous soft tissue biopsy device which leverages the real-time tissue characterization capability of its radiofrequency (RF) spectroscopy technology.

Time March 29, 2019
arrow
Technology | Interventional Radiology

The U.S. Food and Drug Administration (FDA) cleared the Ion endoluminal system from Intuitive Surgical Inc. to enable minimally invasive biopsy in the peripheral lung.

Time February 20, 2019
arrow
News | Prostate Cancer

Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two companies work to improve the way prostate cancer is visualized and detected. Cambridge Consultants is applying deep learning to high-resolution micro-ultrasound imaging to identify potential suspicious regions of tissue and inform urologists who may want to consider this additional data in their biopsy protocol. Early results show real promise, according to the companies.

Time February 12, 2019
arrow
News | Breast Biopsy Systems

A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce unnecessary breast biopsies, according to a new study appearing in the journal Radiology

Time January 17, 2019
arrow
Videos | Radiation Oncology

Aadel Chaudhuri, M.D., assistant professor of radiation oncology, Washington University, St. Louis, Mo., explains his ...

Time November 07, 2018
arrow
News | Radiation Oncology

October 30, 2018 — A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to ...

Time October 30, 2018
arrow
Technology | Breast Biopsy Systems

Leica Biosystems announced the U.S. launch of MammoPort, the first integrated specimen containment and transport system for breast tissue biopsies.

Time October 03, 2018
arrow
Subscribe Now